GemVax & KAEL Co.,Ltd. Logo

GemVax & KAEL Co.,Ltd.

Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.

082270 | KO

Overview

Corporate Details

ISIN(s):
KR7082270000
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노11로 58, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GemVax & KAEL Co., Ltd. is a company with a dual-business structure. Its Environmental Control division manufactures and sells contaminant control solutions, including coating resins and filters, for the semiconductor and display industries. This established business provides the financial foundation for its Bio division, a clinical-stage biopharmaceutical arm focused on developing novel therapeutics. The Bio division's lead candidate is GV1001, a telomerase-derived peptide being developed as a treatment for neurodegenerative diseases, including Alzheimer's disease and Progressive Supranuclear Palsy, and is advancing into late-stage clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 47.6 KB
2025-09-16 00:00
Share Issue/Capital Change
주요사항보고서(제3자의신주인수권부사채매수선택권행사)
Korean 19.5 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.1 KB
2025-09-12 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.11)
Korean 3.3 MB
2025-09-05 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 50.6 KB
2025-09-02 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 30.2 KB
2025-08-29 00:00
Registration Form
[정정제출요구]증권신고서(지분증권) (2025.11)
Korean 2.9 MB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.3 KB
2025-08-18 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 51.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-14 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 50.7 KB
2025-08-04 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 51.8 KB
2025-07-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB

Automate Your Workflow. Get a real-time feed of all GemVax & KAEL Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GemVax & KAEL Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GemVax & KAEL Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.